AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Salarius Pharmaceuticals, Inc. Director's Dealing 2021

Aug 17, 2021

35494_dirs_2021-08-17_bc207ab6-9c77-4a7f-a10e-e273a2fa1a2c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Salarius Pharmaceuticals, Inc. (SLRX)
CIK: 0001615219
Period of Report: 2021-08-17

Reporting Person: Arthur David J. (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-17	Common Stock	P	2000	$0.899	Acquired	100247	Indirect
2021-08-17	Common Stock	P	2000	$0.892	Acquired	102247	Indirect

Footnotes

F1: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose